Hosted on MSN11h
Canaccord Genuity Upgrades Vertex Pharmaceuticals (VRTX)
Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $467.00 Price Target at Barclays
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by analysts at Barclays from $435.00 to $467.00 in a research report issued to clients and investors on ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $520.00
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective upped by equities researchers at Truist Financial from $460.00 to $520.00 in a research report issued on Tuesday,Benzinga ...
Tracking Tweedy Browne Portfolio - Q4 2024 Update
Tweedy Browne’s 13F portfolio value decreased from $2.10B to $1.48B. Click here to read more about the trades and holdings of ...
Vertex Pharmaceuticals SVP Ambrose sells shares for $632,726
Kristen Ambrose, Senior Vice President and Chief Accounting Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotechnology company with strong financial health according ...